GlassScriptPhysician profile
Sergio W Larach
NPI 1790744878
$3,699.99
in general payments reported to CMS, 2019-2025
19 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $192 · 2021: $125 · 2022: $318 · 2023: $1,040 · 2024: $1,135 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,417 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.77 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $660.69 | 2019-2024 | Da Vinci Surgical System |
| Medtronic, INC. | $445.16 | 2023-2024 | Interstim |
| Axonics, INC. | $429.64 | 2022-2023 | Axonics |
| Thd America, INC. | $403.44 | 2021-2024 | |
| Ethicon US, LLC | $286.56 | 2019-2025 | Echelon Endopath, Harmonic, Enseal |
| Conmed Corporation | $252.57 | 2019-2022 | |
| Ethicon INC. | $244.92 | 2024 | |
| Medtronic USA, INC. | $206.88 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $186.30 | 2019-2025 | Exparel |
| Cumberland Pharmaceuticals, INC. | $140.99 | 2024-2025 | Caldolor |
| Aimmune Therapeutics, INC. | $111.16 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $108.88 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $97.28 | 2023 | Dupixent |
| Tela Bio, INC. | $39.34 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.15 | 2022-2024 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $21.88 | 2022 | |
| Enterra Medical, INC. | $17.16 | 2024 | |
| Abbvie INC. | $13.99 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$59,400.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Larach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.